NCT04963712View on ClinicalTrials.gov

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

July 22, 2022

Study Completion Date

August 11, 2022

Conditions
HIV-1-infection
Interventions
DRUG

Zadaxin

1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.

Trial Locations (1)

Unknown

Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Public Health Clinical Center

OTHER_GOV

NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder | Biotech Hunter | Biotech Hunter